Practical issues with COMT inhibitors in Parkinson's disease

Neurology

Volumn 55, Issue 11 SUPPL. 4, 2000, Pages

  Waters, C ^a   Reichmann, ^a   Dingemanse, ^a   Jenner, ^a   Obeso, ^a   Schapira, ^a   Nutt, ^a   Koller, ^a   Hubble, ^a   Kieburtz, ^a   Sch apira, ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; TOLCAPONE;

ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; HUMANS; NITROPHENOLS; PARKINSON DISEASE;

EID: 0034642331     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa-related fluctuations
2. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial
3. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
4. Entacapone enhances the responses to levodopa in parkinsonian patients with motor fluctuation
5. Tolcapone improves motor function in parkinsonian patients with the 'wearing off' phenomenon: A double-blind, placebo-controlled, multicenter trial
6. Tolcapone and hepatotoxic effects